Cell & Gene: The Podcast
The Future of CAR-T with Bristol Myers Squibb's Lynelle Hoch
Aug 31, 2023
Lynelle Hoch, SVP at Bristol Myers Squibb, discusses the near-term future of CAR-T therapy, innovations in the CGT sector, and Bristol Myers Squibb's plans in auto-immune diseases. Challenges in treating solid tumors and personal lives of the hosts are also explored.
25:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Bristol Myers Squibb is working on expanding the usage of CAR-T therapies to broader patient populations and exploring dual targeting approaches to improve response rates and persistence in patients.
- One of the major challenges in cell therapy is scaling the delivery of therapies to a larger number of patients. Bristol Myers Squibb is working on strategies to bring their cell therapies to more patients by expanding access and optimizing gene edits for scalability.
Deep dives
Focus on In-Line Assets and Pipeline Expansion
Bristol Myers Squibb (BMS) is actively working on their in-line assets by bringing CAR-T therapies targeting CD19 in lymphoma and BCMA in multiple myeloma into earlier lines of therapy. They are working with health authorities to expand the usage of these therapies to broader patient populations. Additionally, BMS has an exciting pipeline with new targets in cell therapy, such as GPRC5D in multiple myeloma and CD19XT in severe lupus. They are exploring dual targeting approaches and combination therapies to improve response rates and persistence in patients. BMS is also investing in research and development to advance next-generation technologies for off-the-shelf cell therapy products and potentially treating solid tumors.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
